Issued 2026-09-16 at $83.64 · now $83.64 (2026-09-16, +0.0% since)
Based on its own history, a month from the 2026-09-16 close, TRNS has typically landed between $69.54 and $100.86 — a range of −16.9% to +20.6% from the issuance price $83.64.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
5,003 overlapping 1 month windows · 2006-09-26 – 2026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.7–56.1%, ≈1,408 obs).
The cone is anchored at the 2026-09-16 issuance close ($83.64) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where TRNS has typically landed a month from the 2026-09-16 close of $83.64 — the range is history, not a prediction.
- now $83.64 (+0.0%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $83.97 (+0.4%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $77.52–$90.42
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $69.54–$100.86
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2012-04-24 | −46.0% | −46.0% | +7.2% |
| 2012-04-20 | −44.6% | −44.6% | +3.1% |
| 2008-12-22 | −44.5% | −45.1% | +3.0% |
| 3 best | |||
| 2022-07-14 | +53.7% | +0.0% | +53.7% |
| 2022-07-15 | +51.5% | +0.0% | +51.5% |
| 2022-07-18 | +48.8% | +0.0% | +48.8% |
5,003 overlapping windows · 2006-09-26 – 2026-09-16 · not cherry-picked
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~20 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Reported insider & political trades
Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.
| Date | Person | Role | Action | Shares @ price | Value | Ownership Δ | vs S&P 1m | vs S&P 6m | Owned after | Filing |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-02 | Dominach Oksana S. | director | Sale | 7,312 @ $85.60 | $626K | −62.7% of holding | not yet — horizon still open | not yet — horizon still open | 4,346 | Form 4 · filed 1 day after the trade |
| 2026-08-07 | Gillette Christopher P. | director | Sale | 504 @ $94.23 | $47K | −71.6% of holding | −9.1% | not yet — horizon still open | 200 | Form 4 · filed 5 days after the trade |
| 2026-08-06 | Cairns Craig D. | director | Purchase | 1,050 @ $93.97 | $99K | +244.2% of holding | −9.8% | not yet — horizon still open | 1,480 | Form 4 · filed 4 days after the trade |
| 2025-01-31 | Cairns Craig D. | director | Purchase | 1,000 @ $77.09 | $77K | +109.9% of holding | +2.3% | −8.4% | 1,910 | Form 4 · filed 3 days after the trade |
| 2025-01-31 | Cairns Craig D. | director | Purchase | 200 @ $76.67 | $15K | +87.0% of holding | +2.3% | −8.4% | 430 | Form 4 · filed 3 days after the trade |
| 2024-10-08 | Gillette Christopher P. | director | Sale | 456 @ $119.95 | $55K | −100.0% of holding | −14.7% | −28.3% | 0 | Form 4 · filed 231 days after the trade |
The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.
117 award / exercise / gift records — not counted as purchases
Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.
| Date | Person | Role | Action | Shares | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-10 | Kaniki Mbago M. | director | Option exercise | 1,587 | 4,180 | Form 4 |
| 2026-09-10 | Haseley Gary J. | director | Option exercise | 1,587 | 0 | Form 4 |
| 2026-09-10 | Dominach Oksana S. | director | Option exercise | 1,587 | 0 | Form 4 |
| 2026-09-10 | Gillette Christopher P. | director | Option exercise | 1,587 | 1,787 | Form 4 |
| 2026-09-10 | Gillette Christopher P. | director | Option exercise | 1,587 | 0 | Form 4 |
| 2026-09-10 | Kaniki Mbago M. | director | Option exercise | 1,587 | 0 | Form 4 |
| 2026-09-10 | Langston Cynthia | director | Option exercise | 1,587 | 3,424 | Form 4 |
| 2026-09-10 | Langston Cynthia | director | Option exercise | 1,587 | 0 | Form 4 |
| 2026-09-10 | Mecca Robert | director | Option exercise | 1,587 | 0 | Form 4 |
| 2026-09-10 | Mecca Robert | director | Option exercise | 1,587 | 2,291 | Form 4 |
| 2026-09-10 | Haseley Gary J. | director | Option exercise | 1,587 | 40,689 | Form 4 |
| 2026-09-10 | Cairns Craig D. | director | Option exercise | 1,587 | 6,590 | Form 4 |
| 2026-09-10 | Cairns Craig D. | director | Option exercise | 1,587 | 0 | Form 4 |
| 2026-09-10 | DePerrior Dawn | director | Option exercise | 1,587 | 2,291 | Form 4 |
| 2026-09-10 | DePerrior Dawn | director | Option exercise | 1,587 | 0 | Form 4 |
| 2026-09-10 | Dominach Oksana S. | director | Option exercise | 1,587 | 5,933 | Form 4 |
| 2026-09-09 | Haseley Gary J. | director | Award / grant | 1,671 | 1,671 | Form 4 |
| 2026-09-09 | Mecca Robert | director | Award / grant | 1,671 | 1,671 | Form 4 |
| 2026-09-09 | Dominach Oksana S. | director | Award / grant | 1,671 | 1,671 | Form 4 |
| 2026-09-09 | Cairns Craig D. | director | Award / grant | 1,671 | 1,671 | Form 4 |
| 2026-09-09 | Kaniki Mbago M. | director | Award / grant | 1,671 | 1,671 | Form 4 |
| 2026-09-09 | Langston Cynthia | director | Award / grant | 1,671 | 1,671 | Form 4 |
| 2026-09-09 | DePerrior Dawn | director | Award / grant | 1,671 | 1,671 | Form 4 |
| 2026-09-09 | Gillette Christopher P. | director | Award / grant | 1,671 | 1,671 | Form 4 |
| 2026-08-13 | Dominach Oksana S. | director | Withheld for tax | 2,688 | 11,658 | Form 4 |
| 2026-08-13 | Dominach Oksana S. | director | Option exercise | 10,000 | 14,346 | Form 4 |
| 2026-08-13 | Dominach Oksana S. | director | Option exercise | 10,000 | 0 | Form 4 |
| 2026-06-22 | Simmons Royal Thomas Jr. | officer | Award / grant | 1,508 | 1,508 | Form 4 |
| 2026-05-27 | Barbato Thomas L | officer | Withheld for tax | 760 | 4,649 | Form 4 |
| 2026-05-27 | West Michael W. | officer | Withheld for tax | 465 | 27,086 | Form 4 |
| 2026-05-27 | Conroy Theresa A. | officer | Withheld for tax | 335 | 2,361 | Form 4 |
| 2026-05-27 | Conroy Theresa A. | officer | Award / grant | 759 | 2,696 | Form 4 |
| 2026-05-27 | Barbato Thomas L | officer | Award / grant | 1,719 | 5,409 | Form 4 |
| 2026-05-27 | IRICK JAIME A | director | Award / grant | 15,043 | 15,043 | Form 4 |
| 2026-05-27 | West Michael W. | officer | Award / grant | 1,051 | 27,551 | Form 4 |
| 2026-05-27 | West Michael W. | officer | Award / grant | 1,807 | 1,807 | Form 4 |
| 2026-05-27 | Barbato Thomas L | officer | Award / grant | 3,925 | 3,925 | Form 4 |
| 2026-05-27 | Conroy Theresa A. | officer | Award / grant | 1,382 | 1,382 | Form 4 |
| 2026-05-27 | Haddad Michael Jacques | officer | Award / grant | 1,382 | 1,382 | Form 4 |
| 2026-05-27 | Johnston Kristina L | officer | Award / grant | 409 | 409 | Form 4 |
Source: SEC Form 4 filings. Each row links to its original filing.
Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.